DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Purchases 9,520 Shares of Novo Nordisk A/S (NYSE:NVO)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 15.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 70,716 shares of the company's stock after purchasing an additional 9,520 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main's holdings in Novo Nordisk A/S were worth $6,083,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Center for Financial Planning Inc. increased its holdings in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the period. Transce3nd LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $39,000. Finally, Albion Financial Group UT grew its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on NVO shares. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Price Performance

Shares of NVO traded up $0.90 during trading hours on Friday, hitting $65.75. The stock had a trading volume of 13,058,660 shares, compared to its average volume of 6,383,307. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The stock has a market capitalization of $295.06 billion, a price-to-earnings ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65. The company's fifty day moving average is $69.21 and its two-hundred day moving average is $85.83. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.